PET and CT Scans in Patients With Locally Advanced Primary Rectal Cancer That Can Be Removed During Surgery
| Status: | Completed |
|---|---|
| Conditions: | Colorectal Cancer, Colorectal Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 120 |
| Updated: | 4/21/2016 |
| Start Date: | September 1999 |
Prospective Evaluation of 18F-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in the Multimodality Management of Locally Advanced Primary Rectal Cancer
RATIONALE: Diagnostic procedures, such as PET and CT scans, may improve the ability to
detect the extent of locally advanced primary rectal cancer and may also help to measure a
patient's response to treatment.
PURPOSE: This clinical trial is studying how well PET and CT scans detect residual or
metastatic disease in patients with locally advanced primary rectal cancer that can be
removed during surgery.
detect the extent of locally advanced primary rectal cancer and may also help to measure a
patient's response to treatment.
PURPOSE: This clinical trial is studying how well PET and CT scans detect residual or
metastatic disease in patients with locally advanced primary rectal cancer that can be
removed during surgery.
OBJECTIVES:
- Determine if fludeoxyglucose F 18 positron emission tomography (FDG-PET) is superior to
CT scan at monitoring rectal cancer response to radiation and chemotherapy by
identifying residual rectal cancer in the rectal wall or pelvic lymph nodes in order to
optimize selection of patients suitable for a sphincter preserving rectal cancer
resection or a local excision.
- Determine the accuracy of FDG-PET in detecting extrapelvic metastatic disease in
primary rectal cancer patients considered operable on the basis of currently accepted
diagnostic work-up, including abdominal CT scan and chest x-ray.
OUTLINE: This is a diagnostic study conducted concurrently with multimodality management.
Within 1-2 weeks prior to starting preoperative radiotherapy/chemotherapy, patients undergo
baseline positron emission tomography (PET) imaging of the thorax, abdomen, and pelvis.
Patients receive fludeoxyglucose F 18 (FDG) IV followed 45 minutes later by PET imaging.
Patients also undergo baseline CT imaging of the abdomen and pelvis. A CT scan of the chest
is obtained if the prestudy chest x-ray is abnormal.
Patients receive preoperative radiotherapy/chemotherapy. Within 4-6 weeks of completion of
radiotherapy/chemotherapy, patients undergo repeat FDG-PET imaging and CT scan. Patients
undergo surgical resection 1-2 weeks later.
PROJECTED ACCRUAL: A total of 125 patients will be accrued for this study within 3 years.
- Determine if fludeoxyglucose F 18 positron emission tomography (FDG-PET) is superior to
CT scan at monitoring rectal cancer response to radiation and chemotherapy by
identifying residual rectal cancer in the rectal wall or pelvic lymph nodes in order to
optimize selection of patients suitable for a sphincter preserving rectal cancer
resection or a local excision.
- Determine the accuracy of FDG-PET in detecting extrapelvic metastatic disease in
primary rectal cancer patients considered operable on the basis of currently accepted
diagnostic work-up, including abdominal CT scan and chest x-ray.
OUTLINE: This is a diagnostic study conducted concurrently with multimodality management.
Within 1-2 weeks prior to starting preoperative radiotherapy/chemotherapy, patients undergo
baseline positron emission tomography (PET) imaging of the thorax, abdomen, and pelvis.
Patients receive fludeoxyglucose F 18 (FDG) IV followed 45 minutes later by PET imaging.
Patients also undergo baseline CT imaging of the abdomen and pelvis. A CT scan of the chest
is obtained if the prestudy chest x-ray is abnormal.
Patients receive preoperative radiotherapy/chemotherapy. Within 4-6 weeks of completion of
radiotherapy/chemotherapy, patients undergo repeat FDG-PET imaging and CT scan. Patients
undergo surgical resection 1-2 weeks later.
PROJECTED ACCRUAL: A total of 125 patients will be accrued for this study within 3 years.
DISEASE CHARACTERISTICS:
- Primary resectable rectal cancer as determined by currently accepted diagnostic
work-up, including CT scan and endorectal ultrasound (EUS)
- Must meet criteria for preoperative radiotherapy and chemotherapy:
- Bulky tumors and/or EUS evidence of T3-4 and/or N1 disease
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Performance status:
- Not specified
Life expectancy:
- Not specified
Hematopoietic:
- Not specified
Hepatic:
- Not specified
Renal:
- Not specified
Other:
- Not pregnant or nursing
- No uncontrolled diabetes mellitus (i.e., greater than 175 mg/dL)
- No intolerance of being inside PET scanner for duration of study
- No vulnerable patients (e.g., mentally retarded or prisoners)
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- See Disease Characteristics
Endocrine therapy:
- Not specified
Radiotherapy:
- See Disease Characteristics
Surgery:
- See Disease Characteristics
We found this trial at
1
site
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
